Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia
Phase of Trial: Phase I/II
Latest Information Update: 06 Jan 2017
At a glance
- Drugs RGX 501 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- 06 Jan 2017 According to a REGENXBIO media release, the sponsor has initiated changes to the protocol intended to broaden the eligible and available patient population.
- 06 Jan 2017 According to a REGENXBIO media release, the company and trial sponsor the University of Pennsylvania had commenced screening for patients with homozygous familial hypercholesterolemia (HoFH) for inclusion in the trial and the patient enrollment anticipated to begin first half 2017.
- 05 Jul 2016 According to Regenxbio media release, company expects to enroll first patient in the second half of 2016.